BIVIライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States...

Stats
本日の出来高	312 670
平均出来高	2.59M
時価総額	26.63M
EPS	$0 ( 2024-02-09 )
次の収益日	( $-0.330 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.410
ATR14	$0.00300 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Do Cuong V	Buy	10 000	Common stock
2024-03-04	Do Cuong V	Buy	5 000	Warrants (right to buy)
2023-12-11	Kim Joanne Wendy	Buy	5 000	Common Stock
2023-11-09	Lang James Paul	Buy	93 500	Stock Option (right to buy)
2023-11-09	Gorlin Steve	Buy	46 358	Common Stock

INSIDER POWER
91.56
Last 94 transactions
Buy: 39 235 676 \| Sell: 4 917 434

ボリューム相関

長: -0.03 (neutral)

短: -0.22 (neutral)

Signal:(48.226) Neutral

Biovie Inc 相関

10 最も正の相関
IONM	0.843
CIDM	0.823
AACG	0.818
GAINL	0.807
CERC	0.806
AMRB	0.802

10 最も負の相関
DBX	-0.895
RMRM	-0.894
PCT	-0.882
PTC	-0.866
NOVT	-0.864
OPEN	-0.861
CVAC	-0.846
XP	-0.845
FTHM	-0.842
EXPI	-0.842

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Biovie Inc 相関 - 通貨/商品

0.22
( neutral )

0.00
( neutral )

-0.21
( neutral )

Biovie Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-266 842 (0.00 %)
EPS:	$-1.550

FY	2023
収益:	$0
総利益:	$-266 842 (0.00 %)
EPS:	$-1.550

FY	2022
収益:	$0
総利益:	$-237 421 (0.00 %)
EPS:	$-0.920

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-10.50

Financial Reports:

No articles found.

Biovie Inc

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.